All News

PSA-based screening for prostate cancer among men older than 50 has decreased since the 2012 USPSTF recommendations.

Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.

Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.

Without patients we have no mission to accomplish; whenever we lose someone to cancer our very identity as cancer fighters is threatened with extinction.

A study showed that prostate cancer patients with bone metastases could have a long-term response to ADT and an acceptable quality of life for 10 or more years.

Denosumab used as an adjuvant therapy in postmenopausal breast cancer patients on aromatase inhibitor therapy cut the risk of fractures in half.

Even in the absence of cranial radiation therapy, survivors of childhood acute lymphoblastic leukemia (ALL) have decreased neurocognitive function years later.

Men with prostate cancer assigned to intermittent ADT experienced more ischemic and thrombotic events than did men assigned to continuous ADT.

Most patients with advanced cancer, and up to 60% of patients with any stage of the disease, experience significant pain. The WHO estimates that 25% of all cancer patients die with unrelieved pain.

Many patients with advanced cancer undergo a wasting syndrome associated with cancer anorexia/cachexia and asthenia. In defining these terms a bit further, anorexia is associated with a marked loss of appetite and/or an aversion to food.

Chronic lymphocytic leukemia (CLL) is a clonal malignancy that results from expansion of the mature lymphocyte compartment. This expansion is a consequence of prolonged cell survival, despite a varied cell.

This management guide covers the risk factors, screening, diagnosis, staging, and treatment of non-Hodgkin lymphoma.

Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most distressing side effects of cancer chemotherapy.

This management guide covers the diagnosis and treatment of early-stage breast cancers, including lobular carincoma in situ (LCIS), ductal carcinoma in situ (DCIS), and both noninvasive and invasive disease.

This management guide covers the risk factors, symptoms, screening, diagnosis, prevention, and staging of breast cancer.

This chapter addresses the diagnosis and management of locally advanced, locally recurrent, and metastatic breast cancer, that is, stages III and IV disease.

This management guide covers the treatment of stage II breast cancer, malignancies with primary tumors > 2 cm that involve ipsilateral axillary lymph nodes and tumors ≤ 5 cm without nodal involvement.

Fatigue and dyspnea are two of the most common symptoms associated with advanced cancer. Fatigue is also commonly associated with cancer treatment and occurs in up to 90% of patients undergoing chemotherapy.

Results from a phase I/II study suggest that the immunotherapy nivolumab is safe and effective in advanced hepatocellular carcinoma (HCC).

Aflatoxin, a naturally occurring toxin produced by certain types of molds, has been found to be associated with an increased risk of gallbladder cancer.

We present some tips and advice from the editorial board of ONCOLOGY on how to make the most at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, including places to go in Chicago, nice spots at McCormick Place, and some recommended presentations and sessions.

A survey showed that cancer patients' attitudes about alternative medicines explained their use more so than demographics and clinical characteristics.

The Federal Trade Commission has charged four US cancer charities with fraud, accusing them of diverting more than $187 million in charitable donations.

Patients with acute myeloid leukemia who had a DNMT3A mutation had poorer disease prognosis, according to an analysis of patients aged 60 years or younger.

A Swedish study found that 3D tomosynthesis screening detected 40% more cases of breast cancer compared with traditional digital mammography.

A prospective study found that a bronchial airway gene-expression classifier improved the diagnostic performance of bronchoscopy for lung cancer detection.

The appearance of bone metastases on FDG PET/CT was influenced by breast cancer histology, with non-FDG-avid lesions more common in invasive lobular carcinoma patients.

Genotyping of African Americans suggest that with regard to somatic driver mutations in non-small-cell lung cancer (NSCLC), black patients do not significantly differ from white patients, according to a new study.

In a mouse model, researchers found that TRAIL-R2 inhibition prevented bone metastases, suggesting a possible therapeutic strategy for breast cancer patients.